In 2025, pharmaceutical litigation is no longer confined to patents—it spans trade secrets, biosimilars, consumer pricing, and antitrust. From AbbVie’s ADC dispute to Amgen’s BPCIA battles and class actions against Kroger, Walgreens, CVS, and Takeda, the courtroom has become as central to pharma as the lab. Our analysis explores how litigation now follows a drug through every stage of its lifecycle—and what companies must do to prepare. Read more...

When Swiss fashion house Vetements asked the Supreme Court to review its trademark fight, it put the doctrine of foreign equivalents squarely in the spotlight. At issue is whether U.S. trademark law should rely on literal translations—or on how consumers actually perceive foreign-language brands. The outcome could reshape protection strategies for global companies. Read more...

Disney and Universal’s lawsuit against Midjourney marks one of the most important copyright battles of the AI era. At stake is whether scraping and training on copyrighted works is fair use or infringement—and the outcome could reshape the future of creative industries. Our analysis unpacks the legal arguments, regulatory signals, and business risks, and explains what companies should do now to prepare for a world where AI and copyright collide. Read more...

The One Big Beautiful Bill Act (OBBBA) and California’s AI transparency law (SB 53) are rewriting the rules for innovation. OBBBA restores immediate tax deductions for U.S. research, while SB 53 forces AI companies to disclose safety protocols and risks. Together, they reshape intellectual property strategy for R&D-driven businesses. Learn how federal tax incentives and state transparency mandates collide—and what it means for your company’s IP, licensing, and compliance. Read more...

The Federal Circuit is sending a clear message: ambiguity in patents won’t survive. In recent decisions—Alnylam v. Moderna and LabCorp v. Qiagen—the court underscored that every word matters, from definitions in specifications to the evidence supporting equivalency. This article explores how the rulings reflect a broader judicial shift toward clarity and predictability, and what it means for innovators, patent drafters, and litigators. For businesses, the takeaway is stark: precision isn’t optional—it’s the key to protecting innovation. Read more...

A proposed 1–5% annual tax on the value of U.S. patents could reshape the cost of protecting innovation. While still under consideration, the measure raises serious questions about valuation, compliance, and long-term IP strategy. We  break down the legal hurdles, industry-specific risks, and proactive steps companies can take now to prepare. Read more...

Tariffs are reshaping more than trade—they’re influencing how innovation is protected and enforced. From reshoring and supply chain shifts to new enforcement strategies at the ITC, tariffs are altering IP risks and opportunities across industries. We explore what this means for automotive, consumer electronics, medical devices, and pharmaceuticals, and how businesses can align IP strategy with today’s trade realities. Read more...

Congress is considering two bills—the Patent Eligibility Restoration Act (PERA) and the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act—that could reshape how U.S. patents are obtained, challenged, and enforced. PERA would redefine what inventions qualify for protection, while PREVAIL would change the rules for post-grant reviews at the Patent Trial and Appeal Board. Together, they signal one of the most significant shifts in patent law in years. Read more...

In today’s deals, intellectual property isn’t just legal fine print—it’s the asset that can make or break value. Too often, buyers discover after closing that they don’t actually own the code, data, or know-how they thought they acquired. This post explores why IP has become central to M&A strategy, the risks of overlooking it in carve-outs and acquisitions, and how leading dealmakers are building IP into their playbooks from day one. If your growth strategy involves buying or selling a business, the real question isn’t just “what’s it worth?”—it’s “will we own the IP that makes it valuable?” Read more...

March-in rights under the Bayh-Dole Act were designed to ensure federally funded inventions serve the public interest, but they’ve rarely been used. This post examines the history of march-in rights, why they remain controversial, and what their potential exercise could mean for research institutions, universities, and industry stakeholders. Read more...

From blog posts to choreography, creative work is valuable—and vulnerable. Many people don’t realize that attribution or disclaimers aren’t enough to keep it safe. In this post, we explain the difference between plagiarism and copyright infringement, clear up common misconceptions, and outline practical steps to protect your work under the law. Read more...